Alkem Arm Makes Binding Offer to Acquire 51-55% Stake in Swiss Medtech Firm Occlutech

New Delhi: Alkem Laboratories Limited announced that its wholly owned subsidiary, Alkem Medtech Private Limited, has made a binding offer dated February 13, 2026, to acquire between 51% and 55% of the total issued equity share capital of Switzerland-based Occlutech Holding AG from certain existing shareholders.

The proposed transaction will be executed for cash consideration, the company said in a regulatory filing under SEBI’s Listing Obligations and Disclosure Requirements (LODR) Regulations.

For giving effect to the proposed acquisition, Alkem Medtech proposes to enter into a Share Purchase Agreement with, inter alia, the selling shareholders of Occlutech and a Shareholders Agreement with, inter alia, the continuing shareholders of Occlutech. The proposed acquisition is expected to be completed on or before 30th June, 2026, or such other date as may be mutually agreed between the parties, subject to customary conditions to closing.

Occlutech is a Swiss limited liability company incorporated in Switzerland with the corporate registration number CHE - 101329851. Occlutech Group is engaged in the business of inter alia developing, manufacturing, and marketing minimally invasive cardiac implants and accessories for the treatment of congenital heart defects, stroke prevention, and heart failure.

For the period January–December 2024, the company reported a turnover of EUR 43.95 million (INR 397.80 crore), a net loss (PAT) of EUR 20.52 million (loss of INR 185.73 crore), and a negative net worth of EUR 3.58 million (negative INR 31.93 crore), based on an EUR/INR closing exchange rate of 89.20 and a 12-month average of 90.51.

For January–December 2025, Occlutech has estimated a turnover of EUR 49.38 million (INR 487.87 crore), EBITDA of EUR 2.10 million (INR 20.79 crore), and a PAT loss of EUR 6.85 million (loss of INR 67.65 crore), calculated using a 12-month average EUR/INR exchange rate of 98.80.

The proposed acquisition does not constitute a related party transaction. None of the promoters/promoter groups/group companies of the company have any interest in Occlutech.

The proposed acquisition enables an entry of the company (through its wholly-owned subsidiary Alkem MedTech Private Limited) into the advanced cardiovascular devices business segment. Occlutech has global presence supported by an extensive distribution network and a portfolio of high‑quality products that adhere to the highest regulatory and quality standards. Its reach is expected to expand further through robust product development.

The proposed acquisition is subject to foreign direct investment clearances to be obtained in Italy and Sweden and a precautionary filing in France.

The proposed transaction values Occlutech Holding AG at a total equity value of EUR 180.70 million. Under the terms of the binding offer, the acquisition contemplates the purchase of at least 51% and up to 55% of Occlutech’s total issued and outstanding equity share capital, thereby providing Alkem Medtech Private Limited with a controlling stake in the company.

Occlutech was incorporated in 2000 and is domiciled in Switzerland. Over a period of time, Occlutech has developed, produced, and commercialized first-class, minimally invasive cardiac implants for congenital heart disease, stroke prevention, and heart failure, all with the mission to improve patients’ lives and address unmet medical needs. Occlutech derives its revenue from various geographies, such as Germany, France, Italy, the United Kingdom, Spain, and Japan, and recently entered the United States of America.